JAMP-ALLOPURINOL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

ALLOPURINOL

Saadav alates:

JAMP PHARMA CORPORATION

ATC kood:

M04AA01

INN (Rahvusvaheline Nimetus):

ALLOPURINOL

Annus:

100MG

Ravimvorm:

TABLET

Koostis:

ALLOPURINOL 100MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/1000

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANTIGOUT AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0103654001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2014-03-06

Toote omadused

_ _
_JAMP-Allopurinol PM_
_ _
_ _
_Page 1 of 26_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION PR
JAMP-ALLOPURINOL
Allopurinol Tablets, USP
Tablets, 100, 200 and 300 mg, oral
USP
Xanthine Oxidase Inhibitor
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Submission Control Number: 266368
Date
of
Initial
Authorization:
March 6, 2014
Date
of
Revision:
August 24, 2022
_ _
_JAMP-Allopurinol PM_
_ _
_ _
_Page 2 of 26_
_ _
RECENT MAJOR LABEL CHANGES
3 Serious Warnings and Precautions Box
08/2022
4 Dosage and Administration, 4.2 Recommended Dose and Dosage
Adjustment
08/2022
7 Warnings and Precautions
08/2022
7 Warnings and Precautions, 7.1.4 Geriatrics
08/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................................................... 5
4.5
Missed Dose
.........